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Introduction
Ovarian cancer is the leading cause of death from
gynecologic malignancies since most ovarian cancers
are diagnosed at an advanced stage [1]. Despite
combinations of chemotherapy agents yielding com-
plete responses in 60–80% of patients with advanced
disease, most patients with ovarian cancer eventually
relapse and become refractory to additional treatment
[2]. Therefore, the long-term survival of patients with
advanced disease rarely exceeds 30%.
The review of el-Deiry showed that failure of
chemotherapy may be caused by development of drug
resistance that is related to multiple mechanisms such
as alterations in drug transport, changes in cellular
proteins involved in detoxification, altered drug target,
changes in DNA repair mechanisms, and increased
tolerance to drug damage [3]. In this review, we sum-
marize the possible mechanisms of the development of
resistance to the chemotherapeutic agents used in
ovarian cancer.
Alterations in Drug Transport
Multiple drug resistance (MDR) is a phenomenon
whereby tumor cells acquire cross-resistance to a variety
of structurally and functionally unrelated compounds.
It is commonly known that some forms of MDR arise
from the overexpression of ATP-binding cassette
transporters such as P-glycoprotein (P-gp), MDR-
associated protein 1, and/or breast cancer resistance
protein (BCRP) [4].
P-gp, a 170,000-Da transport protein, functions as
an energy-dependent efflux pump for a number of drugs
and is responsible for decreased drug accumulation
within cells, thereby causing MDR [5]. Amplification or
overexpression of the P-gp family of membrane transport
proteins such as multidrug resistance protein (MRP),
which act as efflux pumps for anticancer agents, will
contribute to physiologic alterations, i.e. intracellular
pH and plasma membrane potentials [3,6].
The human MRP1 gene is located on chromosome
16 at p13.1, spans about 194 kb, and is composed of 31
exons [7]. The originally published MRP1 cDNA encodes
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1,531 amino acids and is predicted to form three
membrane-spanning domains and two nucleotide-
binding domains [8–10]. To date, six splice variant
sequences of MRP1 besides the one mentioned above
have been deposited in the National Center for
Biotechnology Information RefSeq database [8]. In
these splice variants, exons 5, 13, 17, 18, 17 and 18, and
30 are skipped, respectively.
MRP1, originally identified from a drug-resistant
lung cancer cell line, is a prototypical member of the
ATP-binding cassette transporter subfamily that has
been associated with MDR [8–10]. Some studies have
demonstrated that overexpression of MRP1 in tumor
cell lines can confer resistance to many natural product
chemotherapeutic agents such as anthracyclines (e.g.
doxorubicin), vinca alkaloids (e.g. vincristine), and
epipodophyllotoxins (e.g. etoposide) by reducing their
cellular accumulation [11–13].
He et al reported that the MRP1 gene undergoes
alternative splicing at a higher frequency in ovarian
tumors than in matched normal tissues. Some of these
splice variants, in which expression of splicing factors
PTB and SRp20 is strongly associated with the alterna-
tive splicing of the MRP1 gene, confer resistance to
doxorubicin [14].
Current strategies to prevent or reverse MDR have
focused primarily on the development of agents that are
competitive inhibitors of P-gp. Development of these
agents for clinical use has been hindered by toxicity and
limited efficacy [15]. In addition, some studies have
indicated that these and related P-gp inhibitors stimulate
MRP1 expression [16]. Alternative strategies involving
the inhibition of transporter expression may offer
superior mechanisms for reversing the MDR phenotype.
Small interfering RNAs (siRNAs) are double-stranded
RNA molecules that induce sequence-specific
degradation of homologous single-stranded RNA. In
plants and insects, siRNA activity plays a role in host cell
protection against viruses and transposons [17,18].
From a biological research perspective, siRNA is a very
powerful technique to “knockdown” specific genes,
thereby enabling the evaluation of their physiologic
roles in Caenorhabditis elegans, Drosophila melanogaster,
and human cells. siRNA technology has several major
advantages over other post-transcriptional gene silencing
techniques (e.g. antisense or gene knockout technology),
in that it is easier to deliver, requires only small doses of
siRNA to produce its silencing effect, and can inactivate
a gene at almost any stage in development.
Duan et al evaluated the utility of siRNA in reversing
paclitaxel resistance in human ovarian cancer cells
selected for resistance by treatment with paclitaxel.
These cells had been characterized previously and exhibit
the classic MDR phenotype accompanied by increased
expression of MRP1 [19]. The study indicated that
siRNA targeted to MRP1 can sensitize paclitaxel-resistant
ovarian cancer cells in vitro, suggesting that siRNA
treatment may represent a new approach to the
treatment of MRP1-mediated drug resistance. Another
study by Wu et al confirmed the effectiveness of siRNA
in inhibiting MRP1 expression and the subsequent
reversal of resistance to paclitaxel [20].
Changes in Cellular Proteins Involved in
Detoxification
el-Deiry showed that the detoxification procedure
involves the glutathione S transferase enzymes (GSTs),
the  major  ant iox idant  g lutath ione (GSH),
metallothioneins, the human homologue of the mut T
gene of Escherichia coli, bleomycin hydrolase, and
dihydrofolate reductase [3]. Among these, the GSTs,
GSH, and metallothioneins have been studied most
extensively and they are described below.
Glutathione and glutathione S transferases
GSH, a nonprotein sulfhydryl, and its associated
enzymes, GSTs, detoxify some chemotherapeutic drugs
such as alkylating agents and platinum-based drugs [5],
and glutathione peroxidase (GPx) removes toxic oxygen
intermediates.
Six families of enzymes, _, μ, /, e, c and 1, have been
identified [21], of which GSTμ1, GST/1, and GSTe1
have been studied most. The GSTμ1 gene is located on
chromosome 1p13.3, the GST/1 gene is located on
chromosome 11q13, and the GSTe1 gene is located on
chromosome 22q11.2. GST_1 and GST_2, the two
major GST_ genes, are mentioned less frequently in the
literature and are located on chromosome 6p12 [21].
The GSTc1 gene has been mapped to chromosome
14q24.3 [22] and the GST11 gene has recently been
characterized [23].
GST_ has a particular role in cellular resistance to
the alkylating agents melphalan and chlorambucil [24],
while nitrosourea detoxification may be carried out by
GSTμ1 [25]. GST/1 is the most prevalent in human
tumors, and transfection experiments in yeast have
demonstrated that it confers resistance to doxorubicin
and chlorambucil [26].
Coughlin and Hall found that the results of some
studies carried out to date do not confirm associations
between GSTμ1, GST/1, and GSTe1 and epithelial
ovarian cancer [27]. However, the associations are
biologically plausible because GSTs metabolize
exogenous and endogenous substances that may have a
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role in ovarian cancer carcinogenesis [28–30]. Studies
that examine associations within specific histologic
types of ovarian cancer are a promising area for further
research.
Metallothioneins
Metallothioneins are a group of low-molecular weight
and cysteine-rich intracellular proteins. The expression
and induction of these proteins are associated with
protection against DNA damage, oxidative stress and
apoptosis [31].
Although metallothionein is a cytosolic protein in
resting cells, it can be translocated transiently to the cell
nucleus during cell proliferation and differentiation.
Cherian et al reviewed a number of studies that showed
increasing expression of metallothioneins in various
human tumors of the breast, colon, kidney, liver, lung,
nasopharynx, ovary, prostate, salivary gland, testes,
thyroid and urinary bladder [31]. However, metallo-
thionein is downregulated in certain tumors such as
hepatocellular carcinoma and liver adenocarcinoma.
In vitro studies using human cancer cells demonstrate
a possible role for p53 and estrogen receptor in the
expression and induction of metallothioneins in epithe-
lial neoplastic cells [31]. However, chemoresistance in
human tumors is a multifactorial phenomenon, and it
is difficult to conclude that metallothionein is a more
crucial factor than others.
Altered Drug Target
Changes in `-tubulin structure
Taxanes represent the most important class of anticancer
agents obtained from plants and have been available in
clinics from the 1990s. Taxanes bind to `-tubulin
subunits and inhibit microtubule dynamics, thereby
blocking cell cycle progression during mitosis at the
metaphase/anaphase transition and activating cell death
[32].
Despite the contribution of taxanes to improving the
quality of life and overall survival of cancer patients,
drug resistance to these compounds represents the
most important clinical problem. Many patients, even
those who respond initially to therapy, fail to respond
further when disease relapses, and a small number do
not even respond at the first cycle of therapy. A variety
of mechanisms have been proposed to explain taxane
resistance, but one of the most prominent mechanisms
seems to be the overexpression of specific `-tubulin
isotypes, as reported by Kavallaris et al [33].
Point mutations in the paclitaxel binding site of `-
tubulin were first described by Giannakakou et al in
cancer cell lines [34], and were later reported to be
associated with drug resistance in lung cancer patients
[35]. However, more recent studies did not find tubulin
mutations in ovarian and lung cancer patients exhibiting
paclitaxel resistance [36,37]. Therefore, the contribution
of tubulin point mutations to inducing the paclitaxel-
resistant phenotype remains debated, and additional
clinical studies are needed to ascertain the frequency of
tubulin mutations in paclitaxel-resistant tumors. Among
the possible mechanisms of paclitaxel resistance, the
most prominent in in vitro systems seems to be the
overexpression of the class III `-tubulin isotype [38].
Mutation of topoisomerase genes
Topoisomerases are nuclear enzymes and members of
the gyrase family, which transiently break and unwind
DNA during DNA replication and transcription. They
are also involved in many cellular activities including
chromosome condensation, DNA recombination, DNA
segregation during mitosis, and DNA repair. Mammalian
topoisomerases are classified into two types (I and II)
based on the number of strands of DNA on which they
act (single versus double) [39]. Topoisomerase I (TopoI),
coded by a single-copy gene on chromosome 20 and
involved in DNA transcription, catalyzes a transient
single-strand DNA break, allows passage of another
single DNA strand through the break, and then reseals
the break. Topoisomerase II (TopoII), coded by a single-
copy gene on chromosome 17 and involved in the
separation of chromosomes for DNA replication,
catalyzes a transient double-strand DNA break allowing
for the passage of another DNA duplex through the
break and then reseals the break. TopoII is expressed
in specific phases of the cell cycle, G2, S, and M, in both
normal and neoplastic cells [39].
TopoI and TopoII play a crucial role in the cell cycle,
and their expression is increased in malignant ovarian
neoplasm compared with borderline tumors. They are
also the target of several chemotherapeutic agents,
such as camptothecin, etoposide, teniposide, novo-
biocin, anthracyclines, and mitoxantrone [40–43].
Although TopoI and TopoII inhibitors are effective
in malignant ovarian neoplasm, Pommier described
that DNA TopoII rather than TopoI is involved in drug
resistance and sensitivity in human tumors [44]. Two
isoforms have been described, Topo-II_ and Topo-II`.
These DNA conformation-controlling nuclear enzymes
are the targets for several widely used anticancer
drugs, including anthracyclines (e.g. doxorubicin) and
epipodophyllotoxins (e.g. etoposide). These drugs exert
their action by stabilizing a reaction intermediate
formed during the catalytic cycle of TopoII. The pre-
sence of this stabilized protein–DNA complex, which is
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called the cleavable complex, interferes with several
processes that take place at the DNA level (transcription
and replication), causing DNA damage and, ultimately,
cell death. TopoII-related drug resistance is caused by a
decrease in cleavable complex formation in the nucleus,
which will lead to less DNA damage and less cell death
[44]. Since topotecan is an inhibitor of TopoI and is
less involved in drug resistance, it may be suitable for
use in drug-resistant ovarian cancer.
Increased DNA Repair Activity
A human ovarian cancer cell line resistant to cis-
diamminedichloroplatinum(II) (DDP) (2780CP) was
compared with its DDP-sensitive parental cell line
(A2780) to determine whether differences in the removal
rate of DNA-bound platinum were related to resistance
[45]. This study indicated that the mechanism of DDP
resistance in the 2780CP cell line is related to an increased
ability to remove platinum-DNA adducts, and not to a
difference in initial DDP binding to DNA.
Parker et al investigated acquired resistance to
cisplatin in human ovarian cancer cells [46]. The same
cell lines, A2780 and A2780/CP70, were studied to
assess their respective characteristics of drug accumu-
lation and efflux, cytosolic inactivation of drug, and
DNA repair. The authors concluded that in these paired
cell lines, alterations in drug uptake/efflux and DNA
repair are the major contributing factors to acquired
resistance to cisplatin.
Zhen et al reported that acquired cellular resistance
to cisplatin may be associated with increased gene-
specific DNA repair efficiency of a specific lesion, the
interstrand cross-link [47]. The study of Johnson et al
also supports a role for DNA repair and alterations in
interstrand cross-link formation in cisplatin resistance
and provides evidence for heterogeneous interstrand
cross-link formation in the genome [48].
The repair of platinum–DNA lesions is believed to
occur primarily by the process of nucleotide excision
repair (NER). NER removes DNA damage as part of an
oligonucleotide 24–32 residues long. DNA damage is
thought to be recognized by the zinc-finger protein XPA
in association with the heterotrimeric replication protein
RPA. The XPA–RPA complex is then believed to recruit
the basal transcription factor TFIIH, a multisubunit
protein that also plays a role in transcription, to the site
of damage [49]. Two subunits of TFIIH, called XPB and
XPD, have helicase activities that are believed to open
up the DNA around the adduct, thus allowing structure-
specific nucleases to incise the DNA. The ERCC1-XPF
heterodimer, a structure-specific endonuclease, is
responsible for cutting the strand on the 5’ side of
the damage, and the XPG protein incises on the 3’ side.
DNA polymerase b or ¡ and accessory proteins, repli-
cation factor C, and proliferating cell nuclear antigen
fill in the gap, and the DNA is joined by the action of
DNA ligase. In addition to the proteins described
above, the incision stage of the reaction requires XPC,
a protein that may be involved in DNA damage
recognition and/or stabilizing an incision reaction
intermediate [50]. The study of Ferry et al supports a
role for ERCC1-XPF endonuclease as a determinant of
increased NER in this platinum resistance model in
ovarian cancer [49]. However, knowledge is currently
limited as to which of these NER proteins may be critical
or rate-limiting in the enhanced DNA repair in platinum-
resistant cell lines.
Increased Drug Damage Tolerance
Apoptosis is a distinct mode of genetically-controlled
programmed cell death that is a complement to cell
proliferation in normal tissues. The ability of a cancer
cell to respond to a chemotherapeutic agent is believed
to be due, in part, to its apoptotic capacity. Increased
chemotherapy damage tolerance is associated with
decreased susceptibility to apoptosis. Moreover, it is
accepted that the process of drug-induced apoptosis is
governed not only by the upregulation of pro-apoptotic
factors or tumor suppressors, but also by modulation of
cell survival factors [51]. A number of genes involved in
either the induction or inhibition of apoptosis, namely
the p53, Akt, and phosphoinositol-3-OH-kinase (PI3K)
gene families, are aberrantly regulated in ovarian cancer
[52,53]. Because of their wide-ranging biologic effects,
deregulation of one or more of these factors may result
in a failure of drug-induced apoptosis.
Aberrent regulation of the apoptotic regulators,
including p53, the inhibitor of apoptosis (IAP) family,
the Akt family, and the death-receptor family, plays a
significant role in the induction and maintenance of
chemoresistance [51]. Cisplatin has been shown to
upregulate the pro-apoptotic factors p53, fas (also
known as CD95), and bax in a number of cell types
[54–56]. However, it also downregulates specific cell
survival factors such as X-linked IAP (Xiap) and the Akt
family [57]. Recent evidence suggests that chemo-
resistance may represent an overall imbalance between
these two phenomena. Mansouri et al showed that the
expression of Xiap and downregulation of fas ligand are
linked to chemoresistance in ovarian carcinoma cells
and may represent one of the potential anti-apoptotic
mechanisms involved during this process [58].
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Caspases are a family of cysteine-dependent
aspartate-directed proteases that play critical roles in
the initiation and execution of apoptosis. Following
activation of the caspase cascade, downstream
molecules are activated, including caspase activated
DNase and acinus (apoptotic chromatin condensation
inducer in the nucleus), leading to chromatin
condensation and 180-basepair DNA laddering, a
hallmark of apoptotic cell death [59]. One of the pro-
teins responsible for caspase-independent chromatin
condensation is apoptosis-inducing factor (AIF). The
AIF gene is localized within the mouse X chromosome
region A6, which is syntenic to the human X chromosome
region Xq25–26 [60]. Ahn et al demonstrated that AIF
is involved in paclitaxel-induced apoptosis in the human
ovarian carcinoma cell line SKOV3 [61].
IAP was first identified in baculovirus [62]. The
human IAP family includes Xiap, human IAP (Hiap)-1
and -2, neuronal apoptosis inhibitor protein (Naip),
survivin, and livin [63]. Xiap is a 55-kDa protein that
directly inhibits the initiator caspase-9 and execu-
tion caspase-3 and -7, attenuating both mitochondria/
cytochrome c- and death receptor-mediated apoptosis
[64]. Cisplatin downregulates Xiap in chemosensitive,
but not chemoresistant, ovarian cancer cells. More-
over, Xiap is a determinant of chemoresistance, since
downregulation of Xiap in chemoresistant cells renders
the cells sensitive to the cytotoxic actions of cisplatin,
while overexpression of Xiap in chemosensitive cells
causes reversion to the chemoresistant phenotype [57,
65].
Death receptors are cell-surface proteins belonging
to the tumor necrosis factor (TNF) superfamily. These
receptors or their downstream effectors play an
important role in regulating apoptosis, cellular growth,
and proliferation. The most widely studied death
receptors are fas, TNF receptor-1 (TNFR1), TNFR2, and
the TNF-related apoptosis inducing ligand (TRAIL)
receptors, all of which are characterized by an
intracellular region of about 80 amino acids termed the
death domain (DD) [51]. The DD motif is essential for
the induction of apoptotic cell death via recruitment of
adapter proteins also containing a DD motif (e.g. fas-
associated death domain, FADD, and TNFR-associated
death domain, TRADD) and formation of a receptor
signaling complex, fas ligand, resulting in intracellular
clustering of DDs and the recruitment of FADD to the
receptor via homologous DD interactions [66].
Alterations in the expression of fas have been
demonstrated in various cancers as a mechanism for
tumor cells to escape from immune surveillance.
Lysophosphatidic acid induces translocation of fas from
the cell membrane to the cytosol, which may provide a
mechanism by which ovarian cancer cells evade fas
ligand-bearing immune cells [67].
Initiator caspases implicated in the death receptor-
mediated apoptotic pathways (e.g. caspase-8) are
activated through interaction with the caspase-
recruitment domain motif of the death receptor-
associating proteins [68]. Downstream execution cas-
pases (e.g. caspase-3 and -7) are subsequently acti-
vated by initiator caspases. Two of the death receptor
pathways, TNF_–TNFR1 and fas ligand–fas, have been
suggested to play an important role in chemoresistance
in ovarian cancer cells. In human ovarian cancer cells,
DNA-damaging agents such as cisplatin can upregulate
fas and fas ligand, resulting in activation of caspase-8
and -3 and induction of apoptosis. In a chemoresistant
variant, cisplatin failed to upregulate fas ligand or
induce apoptosis [69]. Fraser et al also supported the
notion that dysregulation of the fas/fas ligand system
may be an important determinant in cisplatin resistance
in ovarian cancer cells [51].
fas-associated death domain-like interleukin-
1`-converting enzyme (FLICE)-like inhibitory protein
(FLIP) is recruited to the death-inducing signaling
complex through FADD, thereby preventing caspase-8
recruitment and activation and downstream apoptotic
events [70,71]. Binding of TNF_ to TNFR2 induces IgB
phosphorylation and degradation and activates nuclear
factor gB (NFgB), which in turn regulates TNF_-induced
apoptosis by inducing the expression of genes that
modulate apoptotic pathways (e.g. IAPs and FLIP).
TNF_ is believed to play an important role in ovarian
cancer biology and tumorigenesis, with concentrations
significantly increased in ovarian cancer patients [72]
and levels of TNF_ expression positively correlated with
tumor grade [73]. Xiao et al demonstrated that TNF_
induces NFgB-mediated FLIP expression, which protects
ovarian cancer cells from the cytotoxic action of the
cytokine [74]. The resistance of ovarian cancer cells to
the cytotoxic action of TNF_ may be associated with the
induction of FLIPs in response to the cytokine. In
addition, since activation of the fas/fas ligand system is
an important mechanism of cisplatin-induced apoptosis
in human ovarian cancer cells [56], the possibility that
FLIP is differentially regulated in chemoresistant ovarian
cancer cells cannot be excluded. Mezzanzanica et al
revealed that the inhibitory protein c-FLIP(L) is involved
in resistance to fas-mediated apoptosis in ovarian
carcinoma cells with wild-type p53 [75].
Many cancers have constitutively activated NFgB,
the elevation of which contributes to cancer cell
resistance to chemotherapeutic agent-induced
apoptosis. Although mitogen-activated protein kinase/
extracellular-regulated kinase kinase-3 (MEKK3) has
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been shown to participate in the activation of NFgB, its
relationship to apoptosis and cancer are unclear.
Samanta et al established that elevated expression of
MEKK3 appears to be a frequent occurrence in breast
and ovarian cancers and that overexpression of MEKK3
leads to increased NFgB activity and increased expression
of cell survival factors and ultimately contributes to cell
resistance to apoptosis [76]. As such, MEKK3 may serve
as a therapeutic target to control cancer cell resistance
to cytokine- or drug-induced apoptosis.
PI3Ks are a family of lipid kinases that play a crucial
role in a wide range of important cellular processes
associated with malignant behavior including cell
growth, migration, and survival. They are heterodimers
with separate regulatory (p85) and catalytic (p110)
subunits. AKT (a subfamily of the serine/threonine
protein kinases) is the only downstream target of PI3K
that has been associated with malignant transformation,
and its activation mediates a variety of cellular responses
including cell growth, transformation, differentiation,
motility, and cell survival. The intermediates of the
PI3K/AKT survival pathway are often altered in human
ovarian cancer, and high levels of PI3K and AKTs have
been linked to poor prognosis and chemoresistance
[77]. Amplification of AKT2 (a candidate oncogene at
19q13) has been demonstrated in breast, ovarian, and
pancreatic cancer. Moreover, the gene that encodes the
p110 subunit of PI3K is amplified in some cases of
ovarian cancer, and the p85 subunit of PI3K is also
targeted for mutation in human cancer [78]. Fraser et al
have demonstrated a role for the PI3K/AKT pathway in
resistance to a number of anti-tumor agents [79]. Yuan
et al have also demonstrated that cells expressing a
constitutively active AKT2 are resistant to cisplatin [80].
The study of Asselin et al indicates that Xiap prevents
apoptosis through PI3K-dependent inhibition of the
caspase cascade, demonstrating a novel mechanism by
which Xiap regulates apoptosis and the possible
involvement of the PI3K/AKT survival pathway in Xiap-
mediated chemoresistance of ovarian cancer cells [81].
The cellular apoptosis susceptibility (CAS) gene is
the human homologue of the yeast chromosome
segregation gene CSE and is located at 20q13.1. It is
related to TNF_-mediated apoptosis, probably because
of its involvement in nuclear transport of apoptosis-
associated proteins [82]. CAS is frequently upregulated
in serous ovarian carcinomas, correlated with apoptosis
and mitotic activity, and is prognostically relevant [83].
The bcl family is a group of apoptosis-regulating
genes that prevent or trigger apoptosis. bcl-2 is a
physiologic inhibitor of programmed cell death
and considered a “generalized cell death suppressor”
gene that directly regulates apoptosis [84]. Through
alternate splicing mechanisms, the bcl-x gene, another
member of the bcl family, encodes two proteins that
exert different functions: bcl-xL, the longer form, inhibits
apoptosis, while the shorter form, bcl-xS, is a dominant
inhibitor of bcl-2, promoting apoptosis [85].
Overexpression of bcl-2 occurs frequently in human
cancers and is associated with tumor cell resistance to
chemotherapeutic agents by preventing the apoptotic
response normally induced by those agents [86]. Yang
et al showed that overexpression of anti-apoptotic
proteins bcl-2 and bcl-xL and downregulation of
caspase-3 activity may be associated with cisplatin
resistance in human ovarian cancer [87].
p53 inhibits progression of stressed cells through
the cell cycle and even induces apoptosis in a desperate
attempt to contain the damage and protect the
organism. The pro-apoptotic activity of p53 is mediated
through the mitochondrial pathway by activation of bcl
family members such as bax. Thus, the p53 protein
provides a critical brake on tumor development [88].
Sasaki et al demonstrated that Xiap downregulation
following adenoviral antisense expression induces
apoptosis in cells with wild-type p53, but not in mutated
or null cells [65]. Xiap downregulation results in caspase-
3 activation, caspase-mediated MDM2 processing, and
p53 accumulation. Restoration of wild-type p53 in p53-
mutated or -null cells significantly enhances the pro-
apoptotic effect of Xiap antisense expression. Down-
regulation of Xiap induces apoptosis in chemoresistant
ovarian cancer cells, a process dependent on p53 status.
Conclusion
Drug resistance of tumor cells is recognized as the
primary cause of failure of chemotherapeutic treat-
ment of ovarian tumors. Drug resistance is a multi-
factorial phenomenon involving multiple interrelated or
independent mechanisms. The relevant mechanisms
that can contribute to drug resistance include: alterations
in drug transport, changes in cellular proteins involved
in detoxification, altered drug target, changes in DNA
repair mechanisms, and increased tolerance to drug-
induced DNA damage. Alterations in specific genes
(oncogenes, tumor suppressor genes, metastasis
suppressor genes) appear to be associated directly with
the loss of chemosensitivity.
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